A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

PHASE2CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

July 19, 2023

Study Completion Date

August 1, 2023

Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
DRUG

LY3857210

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (30)

16635

Altoona center for clinical research, Duncansville

30189

North Georgia Clinical Research, Woodstock

32720

Accel Research Sites- Clinical Research Unit, DeLand

32806

Synexus Clinical Research US, Inc - Orlando, Orlando

33135

Suncoast Research Group, Miami

33136

University of Miami Don Suffer Clinical Research Building, Miami

33165

New Horizon Research Center, Miami

33781

Synexus Clinical Research US, Inc., Pinellas Park

34470

Renstar Medical Research, Ocala

45432

META Medical Research Institute, Dayton

48706

Great Lakes Research Group, Inc., Bay City

58104

Lillestol Research, Fargo

60611

Northwestern University, Chicago

63303

StudyMetrix Research, City of Saint Peters

65807

Clinvest Headlands Llc, Springfield

78229

Synexus Clinical Research - St. Petersburg, San Antonio

78731

FutureSearch Trials of Neurology, Austin

83404

Rocky Mountain Clinical Research, Idaho Falls

85053

Arizona Research Center, Phoenix

85224

Synexus Clinical Research US, Inc., Chandler

92103

Artemis Institute for Clinical Research, San Diego

92503

Artemis Institute for Clinical Research, Riverside

98007

Northwest Clinical Research Center, Bellevue

98057

Rainier Clinical Research Center, Renton

06517

CMR of Greater New Haven, LLC, Hamden

02131

Boston Clinical Trials, Boston

01844

ActivMed Practices and Research, Methuen

02451

MedVadis Research Corporation, Waltham

00716

Ponce Medical School Foundation Inc., Ponce

00909

Latin Clinical Trial Center, San Juan

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY